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Response to I. Batinic-Haberle et al.
Harald H.H.W. Schmidt,1 Roland Stocker,2,3 Gøran Paulsen,4 Pietro Ghezzi,5 Dennis Riley,6
Andreas Daiber,7 and Antonio Cuadrado8–11
To the Editor:
The letter by Batinic-Haberle et al. (3) in response toour review (7) is symptomatic for our exciting field of
redox biology and medicine, although we disagree with its
aggressive and in part nonscientific style. Their focus appears
to be on redox biology, whereas the focus of our review was
on redox medicine, in particular those drugs and applications
already in clinical practice or in advanced clinical develop-
ment rather than of ‘‘potential’’ or ‘‘future’’ clinical rele-
vance. It was beyond the scope of our review to address the
wide field of redox biology or experimental antioxidant re-
agents. Batinic-Haberle et al. (3) provide a good overview of
redox-active compounds that, based on preclinical data,
might hold some promise for clinical developments [see table
1 in (3)]. To our knowledge, however, just a few of these
compounds had entered a phase I trial at the time of writing
our review, and none of them had progressed to phase II.
One exception is mitoQ for which several phase II trials have
been carried out in Parkinson’s disease, aging, nonalcoholic
fatty liver disease, and hepatitis C, although none of these
trials has been conclusive. In addition, the phase III study
2CARE for Huntington’s disease has been halted prema-
turely as a result of lack of efficacy of coenzyme Q10 (http://
huntingtonstudygroup.org/tag/2care/).
Batinic-Haberle et al. (3) specifically criticize that super-
oxide dismutase (SOD) mimetics were not mentioned, when
in fact our review did mention some of these compounds,
although maybe not the ones favored by these authors. AEOL
10150 may be an interesting antioxidant, but it has been at an
early clinical stage of development for many years. More-
over, a phase I trial with amyotrophic lateral sclerosis (also
known as Lou Gehrig’s disease and Charcot disease) patients
in 2005 did apparently not progress, and in January 2015, the
FDA put a clinical hold on AEOL 10150 (www.marketwired
.com/press-release/aeolus-announces-response-fda-clinical-
hold-plan-clinical-development-aeol-10150-otcqb-aols-
1981367.htm). MnSOD mimetics were also discussed in
cancer prevention and chronic obstructive pulmonary dis-
ease, but clinical trials are lacking (5). Other related com-
pounds for which the authors of the letter appear to have a
special interest, such as BMX-010 and BMX-001, are, to our
knowledge, still in phase I, and we note that some of the
authors of the letter hold patents for some of these com-
pounds (4) and are supported by the company developing
them (i.e., Biomimetix Pharmaceutical, Inc).
Conversely, the SOD mimetic mentioned in our review,
GC4419, as being, at that time, in phase IIa was meanwhile
shown to protect patients from side effects of radiotherapy
(www.evaluategroup.com/Universal/View.aspx?type=Story
&id=616252). Based on these clinical trial results, the US
FDA has granted ‘‘Fast-Track’’ status to this agent in De-
cember 2015 and the compound is now in a phase IIb/IIIa
human clinical trial in the United States at several major
cancer treatment centers and shall be completed in approxi-
mately 1–2 years. To the best of our knowledge, this devel-
opment stage is the most advanced in the field and it is thus
appropriate to have focused on this compound.
We note that the letter of Batinic-Haberle et al. (3) also
contains a textbook-style lecture on SOD catalysis being a
one-electron process. We agree, of course, that true SOD
catalysis is a one-electron process. However, the same is not
the case for the Mn(porphyrin) complexes described by
Batinic-Haberle et al. (3), as these also carry out multiple
electron processes. For example, the same group reported
Mn(porphyrin) complexes to also be good ‘‘catalase’’
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mimics (2) and others described them as efficient perox-
ynitrite decomposition catalysts (8). Thus, they are not only
selective for superoxide removal but also react with the
product of the dismutation, hydrogen peroxide, and the
secondary oxidant, peroxynitrite. This may or may not be
clinically useful or relevant, but mechanism is something
that must be noted when discussing pharmacology of a
pharmaceutical agent.
Furthermore, it is irritating that the authors attempt to
discount other compounds that are currently in human clin-
ical trials [e.g., Mn(II)pentaazamacrocyclic ligand com-
plexes] by claiming that they are acid unstable. This is
misleading given that some of the authors of this letter have
reported previously on the high kinetic and thermodynamic
stability of members of this class of compounds (e.g.,
M40403) (6). In fact, compounds of this class, including
GC4419, are largely unmetabolized (>90% unchanged) and
excreted almost entirely intact (1).
In summary, given the focus of our review on the advanced
clinical stage of antioxidant drugs, we consider it free of obvious
bias, including conflict of interest. By comparison, it would have
been appropriate for the authors of the letter, in the version
provided to us, to state any potential conflict of interest that may
have contributed to their choice of compound(s).
References
1. Aston K, Rath N, Naik A, and Slomczynska U. Computer-
aided design (CAD) of Mn (II) complexes: Superoxide dis-
mutase mimetics with catalytic activity exceeding the native
enzyme. Inorg Chem 40: 1779–1789, 2001.
2. Batinic-Haberle I, Tovmasyan A, and Spasojevic I. An ed-
ucational overview of the chemistry, biochemistry and
therapeutic aspects of Mn porphyrins – From superoxide
dismutation to H2O2-driven pathways. Redox Biol 5: 43–65,
2015.
3. Batinic-Haberle I, Tovmasyan A, and Spasojevic I. Anti-
oxidants in translation medicine–Commentary. Antioxid Re-
dox Signal 24: 518–524, 2016.
4. Evans MK, Tovmasyan A, Batinic-Haberle I, and Devi GR.
Mn porphyrin in combination with ascorbate acts as a pro-
oxidant and mediates caspase-independent cancer cell death.
Free Radic Biol Med 68: 302–314, 2014.
5. Robbins D and Zhao Y. Manganese superoxide dismutase in
cancer prevention. Antioxid Redox Signal 20: 1628–1645,
2014.
6. Salvemini D and Riley DP. Nonpeptidyl mimetics of su-
peroxide dismutase in clinical therapies for diseases. Cell
Mol Life Sci 57: 1489–1492, 2000.
7. Schmidt HHHW, Stocker R, Vollbracht C, Paulsen G, Riley
D, Daiber A, and Cuadrado A. Antioxidants in translational
medicine. Antioxid Redox Signal 23: 1130–1143, 2015.
8. Valez V, Cassina A, Batinic-Haberle I, Kalyanaraman BB,
Ferrer-Sueta G, and Radi R. Peroxynitrite formation in nitric
oxide-exposed submitochondrial particles: Detection, oxi-
dative damage and catalytic removal by Mn-porphyrins.
Arch Biochem Biophys 529: 45–54, 2013.
Address correspondence to:
Dr. Antonio Cuadrado






Dr. Harald H.H.W. Schmidt








Date of first submission to ARS Central, January 29, 2016;
date of acceptance, February 6, 2016.
Abbreviation Used
SOD¼ superoxide dismutase
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